Lanting Gao1, Changlu Wang1, Mina Liu1, Wentao Fang2, Changxing Lv1, Xiaolong Fu1. 1. Department of Radiation Oncology, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China. 2. Department of Thoracic Surgery, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China.
Abstract
OBJECTIVES: The aim of this study was to evaluate the efficacy of adjuvant chemotherapy (ACT) for thymic squamous cell carcinoma after completely resection. METHODS: Patients with thymic squamous cell carcinoma treated with complete resection between January 2009 and December 2016 were retrospectively identified. Kaplan-Meier analysis was used to summarize the time-to-event variables. Univariable and multivariable Cox proportional hazards regression analyses were performed. RESULTS: A total of 116 patients were analysed with 44 patients in the non-ACT group and 72 patients in the ACT group. No significant difference was found in the 5-year recurrence-free survival (RFS) rate (58.1% vs 51%, P = 0.33) or the 5-year overall survival (OS) rate (77.7% vs 67.1%, P = 0.26) between the ACT group and the non-ACT group. Masaoka stage was the only independent prognostic factor for both RFS and OS. Subgroup analysis showed significant improvement in 5-year RFS for Masaoka stage II patients (P = 0.035) and 5-year OS (P = 0.036) for Masaoka stage III patients when comparing ACT with non-ACT. No chemotherapy-related death occurred. The most frequent adverse effect higher than grade 3 was neutropenia. CONCLUSIONS: For completely resected thymic squamous cell carcinoma, ACT significantly improved the 5-year RFS in Masaoka stage II patients and the 5-year OS in Masaoka stage III patients.
OBJECTIVES: The aim of this study was to evaluate the efficacy of adjuvant chemotherapy (ACT) for thymic squamous cell carcinoma after completely resection. METHODS: Patients with thymic squamous cell carcinoma treated with complete resection between January 2009 and December 2016 were retrospectively identified. Kaplan-Meier analysis was used to summarize the time-to-event variables. Univariable and multivariable Cox proportional hazards regression analyses were performed. RESULTS: A total of 116 patients were analysed with 44 patients in the non-ACT group and 72 patients in the ACT group. No significant difference was found in the 5-year recurrence-free survival (RFS) rate (58.1% vs 51%, P = 0.33) or the 5-year overall survival (OS) rate (77.7% vs 67.1%, P = 0.26) between the ACT group and the non-ACT group. Masaoka stage was the only independent prognostic factor for both RFS and OS. Subgroup analysis showed significant improvement in 5-year RFS for Masaoka stage II patients (P = 0.035) and 5-year OS (P = 0.036) for Masaoka stage III patients when comparing ACT with non-ACT. No chemotherapy-related death occurred. The most frequent adverse effect higher than grade 3 was neutropenia. CONCLUSIONS: For completely resected thymic squamous cell carcinoma, ACT significantly improved the 5-year RFS in Masaoka stage II patients and the 5-year OS in Masaoka stage III patients.
Authors: Frank C Detterbeck; Hisao Asamura; John Crowley; Conrad Falkson; Giuseppe Giaccone; Dori Giroux; James Huang; Jhingook Kim; Kazuya Kondo; Marco Lucchi; Mirella Marino; Edith M Marom; Andrew Nicholson; Meinoshin Okumura; Enrico Ruffini; Paul van Schil; Kelly Stratton Journal: J Thorac Oncol Date: 2013-12 Impact factor: 15.609
Authors: Matthew W Jackson; David A Palma; D Ross Camidge; Bernard L Jones; Tyler P Robin; David J Sher; Matthew Koshy; Brian D Kavanagh; Laurie E Gaspar; Chad G Rusthoven Journal: J Thorac Oncol Date: 2017-01-25 Impact factor: 15.609
Authors: Edward S Kim; Joe B Putnam; Ritsuko Komaki; Garrett L Walsh; Jae Y Ro; Hyung Ju Shin; Mylene Truong; Hojin Moon; Steven G Swisher; Frank V Fossella; Fadlo R Khuri; Waun K Hong; Dong M Shin Journal: Lung Cancer Date: 2004-06 Impact factor: 5.705
Authors: James Huang; Nabil P Rizk; William D Travis; Gregory J Riely; Bernard J Park; Manjit S Bains; Joseph Dycoco; Raja M Flores; Robert J Downey; Valerie W Rusch Journal: J Thorac Cardiovasc Surg Date: 2009-07 Impact factor: 5.209